Header cover image

Hong Kong (HSI) Healthcare Sector Analysis

UpdatedMar 18, 2024
DataAggregated Company Financials
Companies194
  • 7D4.1%
  • 3M-12.2%
  • 1Y-34.3%
  • YTD-12.4%

The Healthcare industry has gained 4.1% in the last week and Hansoh Pharmaceutical Group up 7.8%. Meanwhile, WuXi Biologics (Cayman) actually underperformed within the industry, shrinking 17% in the last week. In the past year, the industry is down 34%. Looking forward, earnings are forecast to grow by 24% annually.

Sector Valuation and Performance

Has the Hong Kong Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 18 Mar 2024HK$1.4tHK$1.4tHK$27.8b11.7x49.3x1x
Wed, 14 Feb 2024HK$1.3tHK$1.4tHK$25.8b11.4x48.6x0.9x
Fri, 12 Jan 2024HK$1.5tHK$1.4tHK$26.0b12.3x57.5x1x
Sun, 10 Dec 2023HK$1.5tHK$1.4tHK$26.3b12.3x58.9x1.1x
Tue, 07 Nov 2023HK$1.7tHK$1.4tHK$25.1b13.5x67.6x1.2x
Thu, 05 Oct 2023HK$1.6tHK$1.4tHK$24.6b12.1x64.9x1.1x
Sat, 02 Sep 2023HK$1.6tHK$1.4tHK$27.3b11.7x58.4x1.1x
Mon, 31 Jul 2023HK$1.7tHK$1.4tHK$14.2b14.2x122.7x1.3x
Wed, 28 Jun 2023HK$1.7tHK$1.3tHK$3.0b14.4x555.8x1.2x
Fri, 26 May 2023HK$1.8tHK$1.4tHK$3.2b14.8x549.8x1.3x
Sun, 23 Apr 2023HK$1.9tHK$1.4tHK$3.9b15.1x501.8x1.4x
Tue, 21 Mar 2023HK$1.8tHK$1.3tHK$1.7b15x1059.6x1.4x
Thu, 16 Feb 2023HK$2.0tHK$1.4tHK$2.1b15.8x930.8x1.5x
Sat, 14 Jan 2023HK$2.1tHK$1.4tHK$2.4b15.6x900.3x1.6x
Mon, 12 Dec 2022HK$1.9tHK$1.3tHK$2.1b14x882x1.4x
Wed, 09 Nov 2022HK$1.7tHK$1.3tHK$1.5b12.7x1109.7x1.3x
Fri, 07 Oct 2022HK$1.5tHK$1.3tHK$3.0b13x505.6x1.2x
Sun, 04 Sep 2022HK$1.7tHK$1.3tHK$3.6b14.6x475.3x1.3x
Tue, 02 Aug 2022HK$1.8tHK$1.3t-HK$1,002,510,437.0014.1x-1781.8x1.4x
Thu, 30 Jun 2022HK$1.9tHK$1.3t-HK$1,283,605,599.0015.4x-1477.2x1.4x
Sat, 28 May 2022HK$1.6tHK$1.3t-HK$2,344,697,573.0013.3x-682.7x1.2x
Mon, 25 Apr 2022HK$1.6tHK$1.3t-HK$2,457,860,259.0013.4x-662.8x1.2x
Wed, 23 Mar 2022HK$1.8tHK$1.4tHK$7.0b13.3x260.3x1.3x
Fri, 18 Feb 2022HK$2.0tHK$1.3tHK$7.9b14.3x253.9x1.5x
Sun, 16 Jan 2022HK$2.3tHK$1.3tHK$7.9b15.6x293.7x1.7x
Tue, 14 Dec 2021HK$2.4tHK$1.3tHK$8.0b14.2x304x1.8x
Thu, 11 Nov 2021HK$2.5tHK$1.3tHK$8.0b14.9x318x1.9x
Sat, 09 Oct 2021HK$2.7tHK$1.3tHK$7.8b15.4x338.6x2x
Mon, 06 Sep 2021HK$3.0tHK$1.3tHK$7.8b17.5x383.1x2.3x
Wed, 04 Aug 2021HK$3.3tHK$1.3tHK$7.5b17.8x438.7x2.6x
Sat, 08 May 2021HK$3.8tHK$1.2t-HK$1,960,161,127.5418.9x-1918.2x3.1x
Price to Earnings Ratio

81074.8x


Total Market Cap: HK$3.4tTotal Earnings: HK$42.2mTotal Revenue: HK$1.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Healthcare Sector Price to Earnings3Y Average 2311.2x202220232024
Current Industry PE
  • Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 49.3x which is lower than its 3-year average PE of 2kx.
  • The 3-year average PS ratio of 1.6x is higher than the industry's current PS ratio of 0.96x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 770% per year over the last three years.
  • Revenues for these companies have grown 5.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare sector?

HK Market1.55%
Healthcare4.12%
Biotech8.34%
Pharma6.48%
Healthtech2.86%
Healthcare Services2.81%
Medical Equipment2.09%
Life Sciences-9.62%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 155x.
    • Analysts are expecting annual earnings growth of 41.6%, which is higher than its past year's earnings decline of 10.6% per year.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 42% over the next 5 years.
  • This is better than its past earnings decline of 11% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
3692 Hansoh Pharmaceutical GroupHK$15.167.8%
+HK$6.5b
11.1%PE32.1x
1093 CSPC Pharmaceutical GroupHK$6.548.8%
+HK$6.3b
-15.6%PE11.7x
6990 Sichuan Kelun-Biotech BiopharmaceuticalHK$147.1023.3%
+HK$6.1b
n/aPS19.7x
1177 Sino BiopharmaceuticalHK$3.279.7%
+HK$5.3b
-23.2%PE29.4x
2453 Concord Healthcare GroupHK$21.9034.4%
+HK$4.0b
n/aPS23.5x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

2269

HK$14.76

WuXi Biologics (Cayman)

7D

-16.6%

1Y

-67.3%

2453

HK$21.90

Concord Healthcare Group

7D

34.4%

1Y

n/a

1952

HK$26.40

Everest Medicines

7D

-7.7%

1Y

59.2%

1177

HK$3.27

Sino Biopharmaceutical

7D

9.7%

1Y

-23.2%

3692

HK$15.16

Hansoh Pharmaceutical Group

7D

7.8%

1Y

11.1%

2268

HK$16.74

WuXi XDC Cayman

7D

-17.1%

1Y

n/a

1541

HK$17.02

ImmuneOnco Biopharmaceuticals (Shanghai)

7D

-12.8%

1Y

n/a

6990

HK$147.10

Sichuan Kelun-Biotech Biopharmaceutical

7D

23.3%

1Y

n/a

9926

HK$51.85

Akeso

7D

8.8%

1Y

20.4%

1099

HK$20.95

Sinopharm Group

7D

-2.3%

1Y

-8.9%

9995

HK$29.75

RemeGen

7D

23.7%

1Y

-40.5%

9885

HK$9.41

YSB

7D

-10.0%

1Y

n/a

1093

HK$6.54

CSPC Pharmaceutical Group

7D

8.8%

1Y

-15.6%

1801

HK$42.30

Innovent Biologics

7D

5.8%

1Y

11.6%

1877

HK$11.02

Shanghai Junshi Biosciences

7D

-5.8%

1Y

-61.1%